Why the study?
Do pharmacologic, electrical, and surgical interventions reduce mortality in patients with Hypertrophic Cardiomyopathy?
Do pharmacologic, electrical, and surgical interventions reduce mortality in patients with Hypertrophic Cardiomyopathy?
Modern management strategies including pharmacologic, electrical, and surgical interventions have successfully reduced HCM mortality to 0.5% per year.
Supports low HCM mortality with modern care; leaves open optimal intervention sequencing in prospective studies.
HCM is the most common genetic disorder of the heart, with 1 case per 200 to 500 persons, and often remains clinically silent. HCM is the most common cause of sudden death in athletes, but pharmacologic, electrical, and surgical interventions have reduced mortality to 0.5% per year.
No takes yet. Share an insight, caveat, or question.
Barry J. Maron (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: